Pharco to develop Presidio\'s NS5A inhibitor PPI-668 for HCV in Kenya
Posted on :Thursday , 4th December 2014
Pharco Pharmaceuticals has entered into an exclusive license agreement to develop and commercialize Presidio’s clinical stage hepatitis C virus (HCV) NS5A inhibitor PPI-668 in Kenya.
With the exclusive license, Pharco will now be able to expand its licensed territory to one or more additional countries in the Middle East and East Africa region.
Pharco Pharmaceuticals vice chairman and chief executive officer Dr Sherine Helmy said: "We believe that PPI-668, in combination with other therapeutic agents offers another potential path to treat and, hopefully, cure patients."
Presidio chief scientific officer Richard Colonno said: "PPI-668 is a potent HCV NS5A inhibitor with a favorable pharmacokinetic profile that has shown high SVR rates in combination with other direct acting antiviral agents."
Under the deal, Pharco will fund clinical development and commercialization of PPI-668 in Kenya, and potentially the Middles East & East Africa region.
In return, Presidio will be eligible to receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Kenya.
Please Select an Option
Expogroup
Expogroup is a full service exhibition organiser with over 28 years experience in International trade exhibitions. Our current portfolio includes 28 annual exhibitions from a diverse range of industries being held across the Middle East & Africa.
EXPOGROUP © 1996 - 2024 | Privacy policy